Agree ARR. We've not seen anything that suggests the science is not correct. Management, well that's another ball of wax. 

Zenith is currently involved with 11 or 13 different trials with 8 or 9 different pharmas. 2 of those trials have moved from 1b-2a trials to 2b trials. This suggests positive progress. Quite a few of the test patients in the 1a mCRPC trial are still with us today more than 4 years after dosing started. From information put out by the company years ago, those patients were not expected to be with us much more than 4 months when they signed onto the program all that time ago.

APB has shown success in many areas as well so it doesn't seem to be a science issue. 

Just after the BETonMACE trial results came out we heard of a BP that wanted to do a 10K person trial or series of trials that would take about 5 years to complete. It won't be long before that timeframe is surpassed by our current path. 

Before making my first investment in this company I had heard that investing in a drug development biotech is the riskiest unleveraged investment a person could make. There is a lot of truth to those words however given what we know so far, a $1 billion price tag is just to pessimistic.

tada